KZR
Kezar Life Sciences, Inc.Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $7M | $0 | $0 | — | — | — | — | — | |
| $23.12M | $33.76M | $65.74M | $85.7M | $51.01M | $38.94M | $30.98M | $27.36M | $18.14M | $6.47M | $7.37M | |
| $18.27M | $18.51M | $23.39M | $26.54M | $20.15M | $15.72M | $11.97M | $9.98M | $6.59M | $2.28M | $1.62M | |
| — | $897K | $1.04M | $1.07M | $1.02M | $1.51M | $1.54M | $1.3M | $690K | $175K | $154K | |
| — | $6.84M | $1.55M | $6.19M | — | — | — | — | — | — | — | |
| $48.84M | $59.11M | $90.61M | $118.42M | $71.16M | $54.66M | $42.95M | $37.34M | $24.73M | $8.75M | $8.99M | |
| -$48.84M | -$59.11M | -$90.61M | -$111.42M | -$71.16M | -$54.66M | -$42.95M | -$37.34M | -$24.73M | -$8.75M | -$8.99M | |
| — | — | — | -1591.77% | — | — | — | — | — | — | — | |
| — | -$58.21M | -$89.57M | -$110.36M | -$70.14M | -$53.15M | -$41.41M | -$36.04M | -$24.04M | -$8.57M | -$8.84M | |
| — | — | $1.59M | $1.55M | $1.19M | $159K | $0 | — | — | — | — | |
| $3.63M | $4.44M | $8.46M | $11.1M | $4.11M | — | — | — | — | — | — | |
| — | -$56.03M | -$83.74M | -$101.87M | — | — | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$45.23M | -$56.03M | -$83.74M | -$101.87M | -$68.24M | -$54.63M | -$41.74M | -$35.09M | -$23.17M | -$8.52M | -$8.99M | |
| — | — | — | -1455.29% | — | — | — | — | — | — | — | |
| -$45M | -$55.87M | -$83.77M | -$101.08M | -$68.87M | -$54.78M | -$41.68M | -$35.08M | -$23.26M | -$8.48M | -$9.14M | |
| USD/shares | — | -$7.66 | -$11.49 | -$14.04 | -$10.13 | -$10.40 | -$9.50 | — | — | — | — |
| USD/shares | — | -$7.66 | -$11.49 | -$14.04 | -$10.13 | -$10.40 | -$9.50 | — | — | — | — |
| shares | — | 7.32M | 7.29M | 7.26M | 6.74M | 5.28M | 4.4M | 1.91M | 1.03M | 59.93K | 33.84K |
| shares | — | 7.32M | 7.29M | 7.26M | 6.74M | 5.28M | 4.4M | 1.91M | 1.03M | 59.93K | 33.84K |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2025: $0 in dividends.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | $0 | $0 | $7,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | -$59,107,000 | -$90,605,000 | -$111,424,000 |
Operating Margin by Segment (%)
| Component | 2023-12-31 |
|---|---|
| Reportable Segment | -1591.8% |